Top Stories
Anti-ageing startup Retro Biosciences closed its next round of funding at a valuation of $1.8 billion, while CVC Capital Partners and Groupe Bruxelles Lambert launched a €10.7 billion cash bid for Recordati.
The combination of neoepitope-based cancer vaccine Tedopi plus Keytruda significantly improved PFS compared to best supportive care in Phase II testing.
The EMA's Committee for Medicinal Products for Human Use backed clearance of camizestrant based on progression-free survival data from the Phase III SERENA-6 study.
BIIB122 missed primary and secondary endpoints in early-stage Parkinson's disease despite strong target engagement signals.
Early efficacy signals for BioNTech/BMS's pumitamig and Pfizer's PF-08634404 sharpen competition with Summit and Akeso's drug.
Conference News
The world’s largest oncology meeting begins on Friday, May 29. Stay tuned for comprehensive coverage of the topics, trends and themes being discussed in and around the conference.In the meantime, here is a look at some of the higher-profile readouts with practice-changing potential that are set to b
Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation)Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic breast...
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitam...
TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and ...
LONDON--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenti...
